By: Lawrence S. Elbaum, Clifford Thau, Patrick Gadson and Sarah C.C. Tishler
On September 12, 2018, the Securities and Exchange Commission charged hedge fund, Lemelson Capital and its adviser, Gregory Lemelson, with perpetrating an unlawful short attack on Ligand Pharmaceuticals. The SEC's complain...